v3.26.1
OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS
 6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS
Accrued liabilities consisted of the following as of June 30, 2026 and December 31, 2025:
(In thousands)JUNE 30,
2026		DECEMBER 31,
2025
Contract research organization and clinical trial costs$5,190 $3,677 
Manufacturing activities11,609 38,657 
Professional, legal and accounting fees3,623 881 
Interest payable— 3,110 
Accrued revenue adjustments6,704 3,486 
Other 3,589 1,529 
$30,715 $51,340 
Accrued compensation and benefits consisted of the following as of June 30, 2026 and December 31, 2025:
(In thousands)JUNE 30,
2026		DECEMBER 31,
2025
Accrued bonuses$5,937 $10,335 
Accrued vacation2,189 2,581 
Accrued restructuring charges178 17,032 
Accrued other802 549 
$9,106 $30,497 
Cash, cash equivalents, and restricted cash included in the Company's condensed consolidated statement of cash flows were as follows:
(In thousands)JUNE 30,
2026		JUNE 30,
2025
Cash and cash equivalents$62,643 $77,734 
Restricted cash1,888 1,870 
Total cash, cash equivalents, and restricted cash$64,531 $79,604